相关实验视频

Updated: May 5, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

杜拉格卢提德在高脂肪饮食引起的肥胖症的小鼠模型中拯救了高丸功能障碍

Sabry M Attia¹, Ali A Alshamrani¹, Sheikh F Ahmad¹

¹Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.

Mutation research. Genetic toxicology and environmental mutagenesis

|August 15, 2024

概括

在肥胖小鼠中,dulaglutide治疗改善了丸功能,扭转了精子损伤和异常. 这表明,对于患有丸功能障碍的肥胖男性来说,有潜在的益处.

科学领域:

生殖内分泌学生殖内分泌学
代谢障碍代谢障碍代谢障碍
药理学药理学是指药理学的学科.

背景情况:

肥胖是丸功能受损的已知危险因素.
杜拉格卢提德的作用,一种用于体重管理的非标签抗糖尿病药物,对肥胖症的丸健康的影响是不充分研究的.
调查杜拉格卢提德的影响对于了解其在非糖尿病肥胖个体中的安全性和有效性至关重要.

研究的目的:

在高脂肪饮食诱导的肥胖小鼠模型中评估杜拉格卢提德对丸功能的影响.
为了确定杜拉格卢提德是否可以减轻与肥胖相关的丸功能障碍.

主要方法:

高脂肪饮食导致小鼠肥胖.
用杜拉格卢提德 (0.6毫克/千克/天) 或盐水治疗五周.
通过精子DNA损伤,染色体异常,精子数量,运动性,形态学和氧化还原平衡来评估丸功能.

主要成果:

肥胖小鼠的丸/体重比下降,精子DNA损伤增加,染色体异常,精子数量和运动率下降,形态缺陷以及氧化还原平衡改变.
在肥胖小鼠中,杜拉古类药物治疗恢复了所有测量的丸参数到控制水平.
对健康小鼠的杜拉古类药物给予没有显著的不良影响.

结论:

杜拉古胺有效地逆转肥胖引起的小鼠丸功能障碍.
这些发现表明,杜拉格卢类药物治疗可能通过改善丸健康来为肥胖男性提供治疗益处.

关键词:

一个DNA链断裂,DNA链断裂.类似于葡萄糖的-1类似物.肥胖并发症肥胖并发症氧化应激是一种氧化应激.

更多相关视频

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...